|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104208 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-12 15:05:27 |
|
注册时间: Date of Registration: |
2025-06-12 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
丙泊酚联合阿芬太尼靶控输注对比间断推注在胃肠镜检查中的应用效果 |
|
Public title: |
The effect of propofol combined with alfentanil target-controlled infusion compared with intermittent bolus injection in gastroenteroscopy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
丙泊酚联合阿芬太尼靶控输注对比间断推注在胃肠镜检查中的应用效果 |
|
Scientific title: |
The effect of propofol combined with alfentanil target-controlled infusion compared with intermittent bolus injection in gastroenteroscopy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
申祥花 |
研究负责人: |
张二飞 |
|
Applicant: |
Shen Xianghua |
Study leader: |
Zhang Erfei |
|
申请注册联系人电话: Applicant telephone: |
+86 150 2911 4959 |
研究负责人电话: Study leader's telephone: |
+86 138 9117 0975 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
294863670@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangerfei09@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省延安市宝塔区北大街43号 |
研究负责人通讯地址: |
陕西省延安市宝塔区北关街43号 |
|
Applicant address: |
43 Peking University Street, Baota District, Yan'an City, Shaanxi Province |
Study leader's address: |
43 Beiguan Street, Baota District, Yan'an City, Shaanxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
延安大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Yan'an University |
||
|
研究负责人所在单位: |
延安大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Yan'an University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IIT—202503012 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
延安大学附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Affiliated Hospital of Yan'an University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-28 00:00:00 |
||
|
伦理委员会联系人: |
王莉 |
||
|
Contact Name of the ethic committee: |
Wang Li |
||
|
伦理委员会联系地址: |
陕西省延安市北关街43号 |
||
|
Contact Address of the ethic committee: |
No. 43, Beiguan Street, Yan'an City, Shaanxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 911 288 1106 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
延安大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Yan'an University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省延安市宝塔区北关街43号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
43 Beiguan Street, Baota District, Yan'an City, Shaanxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-selected topics (self-funded) |
||||||||||||||||||||||
|
Target disease: |
hypoxemia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究通过观察丙泊酚联合阿芬太尼靶控输注在胃肠镜检查中的临床效果,为无痛胃肠镜麻醉提供更佳的给药方式。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study observed the clinical effect of propofol combined with alfentanil target-controlled infusion in gastroenteroscopy, providing a better way of administration for painless gastroenteroscopic anesthesia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
① 患者要求做无痛胃肠镜检; ② 年龄20-70岁; ③ BMI:18-28kg/m2; ④ 美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级Ⅰ~Ⅲ级; ⑤ 签署麻醉知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1.The patient requested a painless gastroenteroscopy; 2. Age 20-70 years old; 3. BMI: 18-28kg/m2; 4. The American Society of Anesthesiologists (ASA) grades I to III; 5. Sign the informed consent form for anesthesia; |
||||||||||||||||||||||
|
排除标准: |
① 严重心血管疾病; ② 预计困难气道; ③ 长期服用阿片类药物过敏体质的患者; ④ 酗酒史; ⑤ 哮喘史; ⑥ 近期上呼吸道感染; ⑦ 糖尿病病史或筛选期空腹血糖≥11.1mmol/L; ⑧ 高血压病史或筛选期SBP≥140mmHg和/或DBP≥90mmHg; ⑨ 服用利血平的高血患者; ⑩ 筛选期开始前2年内有吸毒史和酗酒; ? 史妊娠期或哺乳期; ? 甲状腺功能亢进病史; ? 精神系统疾病及长期服用精神类药物史及认知功能障碍; ? 睡眠呼吸暂停; ? 慢性肺部疾病; ? 癫痫病史; ? 有严重肝肾功能不全; ? 6个月内发生过脑梗或心梗的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. severe cardiovascular disease; 2. Expected difficult airway; 3. Patients with long-term opioid allergy; 4. History of alcoholism; 5. History of asthma; 6.Recent upper respiratory tract infections; 7.Fasting blood glucose ≥ 11.1mmol/L during diabetes history or screening period; 8.Hypertensive history or screening period SBP >= 140mmHg and/or DBP >= 90mmHg; 9.Patients with high blood pressure who take reserpine; 10.A history of drug and alcohol abuse within two years before the start of the screening period; 11.History of pregnancy or breastfeeding; 12.History of hyperthyroidism; 13.Mental illness, long-term use of psychotropic drugs, and cognitive impairment; 14.Sleep apnea; 15.Chronic lung diseases; 16.History of epilepsy; 17.Have severe hepatorenal insufficiency; 18.Patients who have had a cerebral or myocardial infarction within 6 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-03-29 00:00:00至 To 2026-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-04-02 00:00:00 至 To 2026-02-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
without |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后6个月,经研究者同意后可邮箱获取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
6 months after the end of the study, it can be obtained by email with the consent of the investigator |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集后保存在病例记录表以及电子采集和管理系统中 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
After data collection, it is stored in case records and electronic collection and management systems |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |